WESTMINSTER, Colo., Jan. 8 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH) today announced that the Company will
participate in the 2007 JP Morgan Healthcare Conference, to be held January
8 -11 in San Francisco. Paul L. Berns, the Company's President and Chief
Executive Officer, will give a 30-minute corporate overview on Wednesday,
January 10 at 9:30 AM PT.
Live and archived web casts of the presentation will be available on
the Company's website: http://www.allos.com.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused
on the development and commercialization of small molecule therapeutics for
the treatment of cancer. The Company has two product candidates in
late-stage clinical development: EFAPROXYN (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in women
with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel, next generation antifolate currently under
evaluation in a pivotal Phase 2 trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The Company is also evaluating RH1,
a targeted chemotherapeutic agent, in a Phase 1 trial in patients with
advanced solid tumors. For additional information, please visit the
Company's website at http://www.allos.com
Safe Harbor Statement
The anticipated presentations will contain forward-looking statements
that involve significant risks and uncertainties, including those to be
discussed in the presentations and others that can be found in the "Risk
Factors" section of the Company's Form 10-K for the year ended December 31,
2005 and in the Company's periodic reports on Form 10-Q and Form 8-K. The
Company does not undertake any obligation to update any forward-looking
statements contained in the anticipated presentations as a result of new
information, future events or otherwise. The Company cautions investors not
to place undue reliance on the forward-looking statements contained in the
presentation. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman Manager, Corporate
Communications of Allos Therapeutics, +1-720-540-5227,
jneiman@allos.com
|
